CA3172681A1 - Methods for preparing tyrosine receptor kinase inhibitors - Google Patents
Methods for preparing tyrosine receptor kinase inhibitors Download PDFInfo
- Publication number
- CA3172681A1 CA3172681A1 CA3172681A CA3172681A CA3172681A1 CA 3172681 A1 CA3172681 A1 CA 3172681A1 CA 3172681 A CA3172681 A CA 3172681A CA 3172681 A CA3172681 A CA 3172681A CA 3172681 A1 CA3172681 A1 CA 3172681A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- formula
- haloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010108P | 2020-04-15 | 2020-04-15 | |
| US63/010,108 | 2020-04-15 | ||
| PCT/US2021/027538 WO2021211882A1 (en) | 2020-04-15 | 2021-04-15 | Methods for preparing tyrosine receptor kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172681A1 true CA3172681A1 (en) | 2021-10-21 |
Family
ID=78083713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172681A Pending CA3172681A1 (en) | 2020-04-15 | 2021-04-15 | Methods for preparing tyrosine receptor kinase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12606565B2 (https=) |
| EP (1) | EP4135700A4 (https=) |
| JP (1) | JP7767301B2 (https=) |
| KR (1) | KR20230011912A (https=) |
| CN (1) | CN115515591B (https=) |
| AU (1) | AU2021255613A1 (https=) |
| BR (1) | BR112022020114A2 (https=) |
| CA (1) | CA3172681A1 (https=) |
| IL (1) | IL296921A (https=) |
| MX (1) | MX2022012437A (https=) |
| WO (1) | WO2021211882A1 (https=) |
| ZA (1) | ZA202209792B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11739096B2 (en) | 2017-12-15 | 2023-08-29 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296921A (en) | 2020-04-15 | 2022-12-01 | Pyramid Biosciences Inc | Methods for making receptor tyrosine kinase inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| CN101242844A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| UA95244C2 (ru) * | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| KR101324804B1 (ko) | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
| MY169791A (en) | 2008-10-22 | 2019-05-15 | Array Biopharma Inc | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP3812387A1 (en) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
| WO2014055928A2 (en) * | 2012-10-04 | 2014-04-10 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| FR3029769A1 (fr) | 2014-12-10 | 2016-06-17 | Tornier Sa | Kit pour une prothese d'epaule |
| CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| JP6475084B2 (ja) | 2015-05-21 | 2019-02-27 | 臼井国際産業株式会社 | トルクセンサ用シャフトの製造設備およびその製造方法 |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| SG11202005237SA (en) * | 2017-12-15 | 2020-07-29 | Pyramid Biosciences Inc | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer |
| IL296921A (en) | 2020-04-15 | 2022-12-01 | Pyramid Biosciences Inc | Methods for making receptor tyrosine kinase inhibitors |
-
2021
- 2021-04-15 IL IL296921A patent/IL296921A/en unknown
- 2021-04-15 CN CN202180024618.XA patent/CN115515591B/zh active Active
- 2021-04-15 CA CA3172681A patent/CA3172681A1/en active Pending
- 2021-04-15 WO PCT/US2021/027538 patent/WO2021211882A1/en not_active Ceased
- 2021-04-15 JP JP2022559980A patent/JP7767301B2/ja active Active
- 2021-04-15 KR KR1020227033977A patent/KR20230011912A/ko active Pending
- 2021-04-15 EP EP21787908.9A patent/EP4135700A4/en active Pending
- 2021-04-15 AU AU2021255613A patent/AU2021255613A1/en active Pending
- 2021-04-15 MX MX2022012437A patent/MX2022012437A/es unknown
- 2021-04-15 BR BR112022020114A patent/BR112022020114A2/pt unknown
- 2021-04-15 US US17/918,880 patent/US12606565B2/en active Active
-
2022
- 2022-09-01 ZA ZA2022/09792A patent/ZA202209792B/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11739096B2 (en) | 2017-12-15 | 2023-08-29 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
| US12486276B2 (en) | 2017-12-15 | 2025-12-02 | Pyramid Biosciences, Inc. | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021211882A1 (en) | 2021-10-21 |
| EP4135700A4 (en) | 2024-04-17 |
| KR20230011912A (ko) | 2023-01-25 |
| US12606565B2 (en) | 2026-04-21 |
| US20230242536A1 (en) | 2023-08-03 |
| JP2023522841A (ja) | 2023-06-01 |
| JP7767301B2 (ja) | 2025-11-11 |
| AU2021255613A1 (en) | 2022-09-29 |
| CN115515591A (zh) | 2022-12-23 |
| EP4135700A1 (en) | 2023-02-22 |
| IL296921A (en) | 2022-12-01 |
| MX2022012437A (es) | 2022-10-27 |
| CN115515591B (zh) | 2024-09-27 |
| BR112022020114A2 (pt) | 2022-11-29 |
| ZA202209792B (en) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202494B2 (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| JP5060957B2 (ja) | 複素環化合物、その製造方法並びに用途 | |
| CN1950371B (zh) | 用作组胺h3受体配体的四氢萘啶衍生物 | |
| JP7425724B2 (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 | |
| HRP20020910A2 (en) | -carboline derivatives useful as inhibitors of phosphodiesterase | |
| WO2014128655A1 (en) | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors | |
| US20080249114A1 (en) | Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments | |
| CA2855950A1 (en) | Kinase modulating compounds, compositions containing the same and use thereof | |
| CN103588792A (zh) | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 | |
| JP7764472B2 (ja) | サイクリン依存性キナーゼ７（ｃｄｋ７）非共有結合阻害剤 | |
| CA2792339A1 (en) | Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors | |
| CA3172681A1 (en) | Methods for preparing tyrosine receptor kinase inhibitors | |
| CN116874503A (zh) | 一种高活性的hpk1激酶抑制剂 | |
| CN117295734A (zh) | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 | |
| JP6120311B2 (ja) | ポリフェノール化合物 | |
| CA3161049A1 (en) | Collagen 1 translation inhibitors and methods of use thereof | |
| WO2022194265A1 (zh) | 一种喹唑啉类化合物、组合物及其应用 | |
| Matloubi Moghaddam et al. | A new and efficient method for the synthesis of pyrazolo [3, 4-d] pyrimidines catalyzed by iodine | |
| HK40098892A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| NZ795530A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof | |
| HK40016100A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250321 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250324 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250324 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260323 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260323 |